Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChariotMS: Cladribine in Advanced Multiple Sclerosis
NCT04695080Phase 3Active, not recruiting
- Sponsor
- Queen Mary University of London
- Start
- Jun 2021
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cladribine in multiple sclerosis (MS), sponsored by Queen Mary University of London. Started Jun 2021; status: active, not recruiting.
02
Drugs
cladribine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04695080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04695080.